Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

References

• Günthard HF, Aberg JA, Eron JJ, et al; Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410–425.10.1001/jama.2014.8722
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al; Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–1263.10.1016/S0140-6736(04)15997-7
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3:279–286.10.1310/3Q91-YT2D-BUT4-8HN6
   PubMedGoogle Scholar
• Squires K, Lazzarin A, Gatell JM, et al; Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011–1019.10.1097/00126334-200408150-00003
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA Approved Drug Products [Internet]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. [Accessed August 29, 2015].
   Google Scholar
• Cohen CJ, Molina J-M, Cassetti I, et al; Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27:939–950.10.1097/QAD.0b013e32835cee6e
   PubMed Web of Science ®Google Scholar
• Nelson MR, Elion RA, Cohen CJ, et al; Rilpivirine versus efavirenz in HIV-1–infected subjects receiving emtricitabine/tenofovir DF: Pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14:81–91.10.1310/hct1403-81
   PubMed Web of Science ®Google Scholar
• Mills AM, Cohen C, DeJesus E, et al; Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate–based single-tablet regimens. HIV Clin Trials. 2013;14:216–223.10.1310/hct1405-216
   PubMed Web of Science ®Google Scholar
• Shalit P. Management of dyslipidemia in patients with human immunodeficiency virus. Rev Cardiovasc Med. 2014;15:S38–S46.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Fisher M, Tebas P, et al; Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335–344.10.1097/QAD.0000000000000087
   PubMed Web of Science ®Google Scholar
• Pinnetti C, Di Giambenedetto S, Maggiolo F, et al; Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. J Int AIDS Soc. 2014;17:19812.
   PubMed Web of Science ®Google Scholar
• Gazaignes S, Resche-Rigon M, Yang C, et al; Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study. J Int AIDS Soc. 2014;17:19796.
   PubMed Web of Science ®Google Scholar
• Rokx C, Verbon A, Rijnders BJA. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF. AIDS Res Human Retroviruses. 2015;31:363–367.10.1089/aid.2014.0278
   PubMed Web of Science ®Google Scholar
• Cazanave C, Reigadas S, Mazubert C, et al; Switch to rilpivirine/emtricitabine/tenofovir single-tablet regimen of human immunodeficiency virus-1 RNA-suppressed patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014. Open Forum Infect Dis. 2015;2: ofv018.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al; Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. The Lancet. 2011;378:229–237.10.1016/S0140-6736(11)60983-5
   PubMed Web of Science ®Google Scholar
• Molina J-M, Cahn P, Grinsztejn B, et al; Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. The Lancet. 2011;378:238–246.10.1016/S0140-6736(11)60936-7
   PubMed Web of Science ®Google Scholar
• Rimsky L, Van Eygen V, Hoogstoel A, et al; 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antiviral Ther. 2013;18:967–977.10.3851/IMP2636
   PubMed Web of Science ®Google Scholar
• Gantner P, Reinhart S, Partisani M, et al; Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: A cohort study. HIV Med. 2015;16:132–136.10.1111/hiv.2015.16.issue-2
   PubMed Web of Science ®Google Scholar
• Surgers L, Valin N, Viala C, et al; Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients. J Acquir Immune Defic Syndr. 1999;2015:e10–e12.
   Google Scholar
• Cohen C, Wohl D, Arribas J, et al; Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28:989–997.10.1097/QAD.0000000000000169
   PubMed Web of Science ®Google Scholar